Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Versus mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced pMMR/MSS Colorectal Cancer
NCT06791512Phase 3Recruiting
- Sponsor
- Jun Huang Lab
- Start
- Jan 2025
- Primary completion
- Dec 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sintilimab and bevacizumab in colorectal cancer (CRC) (2 arms), sponsored by Jun Huang Lab. Primary endpoint: Disease-Free Survival Rate at 3 years. Started Jan 2025; status: recruiting.
02
Drugs
sintilimabbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06791512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06791512.